Form 8-K - Current report:
SEC Accession No. 0000950170-25-097078
Filing Date
2025-07-21
Accepted
2025-07-21 07:31:02
Documents
18
Period of Report
2025-07-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20250721.htm   iXBRL 8-K 90582
2 EX-3.1 sabs-ex3_1.htm EX-3.1 169362
3 EX-4.1 sabs-ex4_1.htm EX-4.1 150192
4 EX-4.2 sabs-ex4_2.htm EX-4.2 150101
5 EX-10.1 sabs-ex10_1.htm EX-10.1 458321
6 EX-10.2 sabs-ex10_2.htm EX-10.2 205709
7 EX-10.3 sabs-ex10_3.htm EX-10.3 37630
8 EX-10.4 sabs-ex10_4.htm EX-10.4 25683
9 EX-99.1 sabs-ex99_1.htm EX-99.1 20939
  Complete submission text file 0000950170-25-097078.txt   1658743

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20250721.xsd EX-101.SCH 48404
20 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20250721_htm.xml XML 6790
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 251135716
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)